Inrebic (Fedratinib)

Fedratinib works by selectively inhibiting the JAK2 enzyme, a central component of the JAK‑STAT pathway that drives abnormal blood cell production in myelofibrosis. Blocking JAK2 reduces downstream signaling, leading to decreased proliferation of malignant hematopoietic cells, reduced cytokine production, and improvement of marrow fibrosis.

The dosing regimen for Inrebic is determined by the prescribing healthcare professional based on the individual patient's clinical condition, liver function, and concomitant medications. Physicians tailor the dose to achieve optimal therapeutic benefit while monitoring safety parameters.

Safety data for fedratinib in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk with their physician.

To request Inrebic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Inrebic (fedratinib) and ruxolitinib are both JAK inhibitors approved for myelofibrosis. Fedratinib is a more selective JAK2 inhibitor, which may offer efficacy in patients who have progressed on or are intolerant to ruxolitinib. Safety profiles differ; for example, fedratinib carries a specific risk of Wernicke encephalopathy, whereas ruxolitinib is associated with different hematologic toxicities.

Inrebic tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect the product from moisture, excessive heat, and direct sunlight. Keep out of reach of children and do not use after the expiry date indicated on the label.

Inrebic is taken orally as a whole tablet with water. Patients should swallow the tablet whole and not crush, split, or chew it unless specifically instructed by a healthcare professional. The medication is usually taken once daily, but exact timing is determined by the prescriber.

The most serious adverse events linked to fedratinib include Wernicke encephalopathy (a neurological disorder related to thiamine deficiency), severe or opportunistic infections, significant hepatic toxicity, and profound myelosuppression such as severe anemia or thrombocytopenia. Prompt medical attention is required if any of these occur.

Inrebic should be avoided in patients with known hypersensitivity to fedratinib or any tablet excipients, those with severe hepatic impairment, active uncontrolled infections, or a history of Wernicke encephalopathy. Caution is also advised for patients on strong CYP3A4 inhibitors or inducers, and for pregnant or breastfeeding women unless the benefit justifies the risk.